Cytodyn Inc (CYDY)

[Saltz]

IMO the current downward pressure on PPS is related to a lack of confidence in managements ability to stay on schedule with the two PIII Clinical Trials. Right now we are in limbo because we are waiting on the results of the meeting with the FDA. The birdies we keep hearing about are chirping the news will be negative. The tendency for the FDA to favor a more stringent path is a given because there first responsibility is safety. So here we are at a bit of a pivotal point. Many believe the results up to this point warrant reducing the Adjunct patients from 150 downward to as low as 30 and a strong possibility of granting BTD. If that happens the timeline is shortened and the end game is in sight and the PPS is on its way to an organic up list. If the FDA stands on the current protocol the timeline is out there in the fog creating less confidence and more uncertainty and the birdies will be chirping I told you so. Regardless the underlying value of Pro-140 hasn't changed significantly for the investor. This investment is all about how long and how much money is it going to take to complete the PIII's. Positive FDA news regarding the PIII Adjunct is pivotal. All this chirping is the opinion that the FDA takes there normal safe position because they can. IMO Pro-140 is a diamond in the rough that can improve the SOC. I also believe it has the FDA's focused consideration which may surprise all those obnoxious birds. The bottom line is NOBODY has a crystal ball. The frustration is measuring managements competence to successfully navigate the FDA's complex requirements. Nader has a board that has experience and gets it. I'm counting on it.